Company Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne.
The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Country | United States |
Founded | 2014 |
IPO Date | Nov 12, 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 41 |
CEO | Claude Maraoui |
Contact Details
Address: 9237 E Via De Ventura Blvd., Suite 105 Scottsdale, Arizona 85258 United States | |
Phone | 480-434-6670 |
Website | journeymedicalcorp.com |
Stock Details
Ticker Symbol | DERM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $10.00 |
CIK Code | 0001867066 |
CUSIP Number | 48115J109 |
ISIN Number | US48115J1097 |
Employer ID | 47-1879539 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Lindsay Allan Rosenwald | Executive Chairman |
Claude Maraoui | Founder, President, Chief Executive Officer and Director |
Joseph M. Benesch | Interim Chief Financial Officer and Corporate Controller |
Andrew J. Zwible | Vice President of Operations |
Ramsey Alloush | General Counsel and Company Secretary |
Robert Nevin | Chief Commercial Officer |
Jaclyn Jaffe | Senior Director of Corporate Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 14, 2024 | 10-Q | Quarterly Report |
May 13, 2024 | 8-K | Current Report |
May 1, 2024 | 8-K | Current Report |
Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
Mar 29, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 8-K | Current Report |
Jan 2, 2024 | 8-K | Current Report |
Dec 15, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
Dec 8, 2023 | 8-K | Current Report |